About Elion Therapeutics
Elion Therapeutics is a company based in New York (United States) founded in 2024 by Kieren Marr.. Elion Therapeutics has raised $81 million across 1 funding round from investors including Deerfield, AMR Action Fund and Illinois Ventures. Elion Therapeutics operates in a competitive market with competitors including Scynexis, F2g, Amplyx Pharmaceuticals, Biosergen and Mycovia Pharmaceuticals, among others.
- Headquarter New York, United States
- Founders Kieren Marr
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
- Legal Name Elion Therapeutics, Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$81 M (USD)
in 1 rounds
-
Latest Funding Round
$81 M (USD), Series B
Jun 17, 2024
-
Investors
Deerfield
& 2 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Funding Insights of Elion Therapeutics
Elion Therapeutics has successfully raised a total of $81M through 1 strategic funding round. The most recent funding activity was a Series B round of $81 million completed in June 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series B — $81.0M
-
First Round
First Round
(17 Jun 2024)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2024 | Amount | Series B - Elion Therapeutics | Valuation | Deerfield |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Elion Therapeutics
Elion Therapeutics has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Deerfield, AMR Action Fund and Illinois Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Founded Year | Domain | Location | |
|
Investments are made in antimicrobial resistance treatment development.
|
Founded Year | Domain | Location | |
|
Early-stage investments are made in deep tech sectors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Elion Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Elion Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Elion Therapeutics Comparisons
Competitors of Elion Therapeutics
Elion Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Scynexis, F2g, Amplyx Pharmaceuticals, Biosergen and Mycovia Pharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developing glucan synthase inhibitors for the treatment of fungal infections.
|
|
| domain | founded_year | HQ Location |
Drugs for systemic fungal diseases are discovered and developed.
|
|
| domain | founded_year | HQ Location |
Broad-spectrum fungal enzyme inhibitors are developed by clinical-stage biopharma.
|
|
| domain | founded_year | HQ Location |
Anti-fungal therapeutics are developed against invasive fungal diseases.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics are developed for recurrent vulvovaginal candidiasis treatment.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Elion Therapeutics
Frequently Asked Questions about Elion Therapeutics
When was Elion Therapeutics founded?
Elion Therapeutics was founded in 2024.
Where is Elion Therapeutics located?
Elion Therapeutics is headquartered in New York, United States. It is registered at New York, New York, United States.
Is Elion Therapeutics a funded company?
Elion Therapeutics is a funded company, having raised a total of $81M across 1 funding round to date. The company's 1st funding round was a Series B of $81M, raised on Jun 17, 2024.
What does Elion Therapeutics do?
Elion Therapeutics was founded in 2024 and is based in New York, United States. The company operates in the biotechnology sector, focusing on the development of treatments for invasive fungal infections. A lead candidate, SF001, is provided as an intravenous infusion in micellar solution form, utilizing the polyene compound Sfu-AM2-19A to address aspergillosis. Research and therapeutic innovation are centered on unmet needs in antifungal care.
Who are the top competitors of Elion Therapeutics?
Elion Therapeutics's top competitors include Scynexis, F2g and Amplyx Pharmaceuticals.
Who are Elion Therapeutics's investors?
Elion Therapeutics has 3 investors. Key investors include Deerfield, AMR Action Fund, and Illinois Ventures.